Capital Impact Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital Impact Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,572	Closed	-$179K	–	136
2021 Q1	$179K	Sell	1,572 -24,010	-94%	-$3.27M	0.06%	106
2020 Q4	$3.54M	Sell	25,582 -25,000	-49%	-$2.97M	0.87%	47
2020 Q3	$4.16M	Buy	50,582 +20,000	+65%	+$1.66M	1.23%	19
2020 Q2	$2.39M	Sell	30,582 -15,340	-33%	-$1.02M	0.8%	57
2020 Q1	$2.04M	Buy	45,922 +1,789	+4%	+$92.9K	0.86%	48
2019 Q4	$1.89M	Hold	44,133	–	–	0.66%	86
2019 Q3	$1.88M	Buy	44,133 +7,968	+22%	+$433K	0.71%	82
2019 Q2	$2.24M	Sell	36,165 -1,693	-4%	-$108K	0.82%	33
2019 Q1	$1.58M	Hold	37,858	–	–	0.7%	65
2018 Q4	$1.58M	Buy	37,858 +9,112	+32%	+$498K	0.68%	68
2018 Q3	$2.29M	Buy	28,746 +1,672	+6%	+$136K	0.79%	43
2018 Q2	$2.06M	Sell	27,074 -4,917	-15%	-$318K	0.76%	44
2018 Q1	$1.63M	Buy	+31,991	New	+$1.61M	0.67%	65

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Impact Advisors's RARE Position: Q2 2021 in Review

Capital Impact Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 1,572 shares — an estimated $179K sold.

Capital Impact Advisors first reported a position in RARE in Q1 2018 and held it in 13 quarters. The position peaked at $4.16M in Q3 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Capital Impact Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Capital Impact Advisors sold 1,572 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $179K.
Capital Impact Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 13 quarters.
Capital Impact Advisors's Ultragenyx Pharmaceutical position peaked at $4.16M in Q3 2020.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Capital Impact Advisors's 13F filing for Q2 2021, filed 17 Aug 2021.